Clinical course of Covid-19 in a cohort of patients with Behçet disease

Epidemiological Profile of Bechcet’s Disease in Hospitalized Patients Infected With SARS-CoV-2 in Brazil: A Serial Case Report and a Literature Review

“…The authors found that the prevalence of COVID-19 among those patients seems to be higher than that among the general population in Spain [10]. The authors hypothesized that continuous tumor necrosis factor inhibitor therapy might increase the prevalence of worse clinical outcomes such as dyspnea; oral glucocorticoids and colchicine apparently did not protect COVID-19-related clinical outcomes in patients with BD [10]. In the same way, Den Otter and collaborators (2022) performed a cohort to investigate the cumulative incidence and the severity of COVID-19 in patients with BD (N = 185) [27] demonstrating a higher risk for COVID-19 without an increase of virus-related mortality [27].…”

“…A total of 8.7% (4) patients had taken antiviral medicine. Regarding the need for intensive care, 39.1% (18 patients) needed intensive care unit support; in addition, 21.7% (10) patients needed invasive ventilatory support, 47.8% (22) patients needed non-invasive ventilatory support and 30.4% (14 patients) did not receive ventilatory support. For discharge criteria, 87.0% (40) patients were discharged under laboratory criteria, while 13.0% (6) patients were discharged under clinical criteria.…”

“…Correa-Rodríguez and collaborators (2021) performed a retrospective study conducted among 244 patients with BD [10]. The authors found that the prevalence of COVID-19 among those patients seems to be higher than that among the general population in Spain [10].…”

“…Correa-Rodríguez and collaborators (2021) performed a retrospective study conducted among 244 patients with BD [10]. The authors found that the prevalence of COVID-19 among those patients seems to be higher than that among the general population in Spain [10]. The authors hypothesized that continuous tumor necrosis factor inhibitor therapy might increase the prevalence of worse clinical outcomes such as dyspnea; oral glucocorticoids and colchicine apparently did not protect COVID-19-related clinical outcomes in patients with BD [10].…”

“…The disease, popularly named coronavirus disease (COVID)-19, was officially declared a pandemic by the World Health Organization on 11 March 2020 [9]. There is a current theory that the risk of severe COVID-19 and its associated complications is considered to be increased in patients with preexisting and underlying medical conditions or comorbidities [10]. In this matter, this theory raises the question of whether patients with autoimmune diseases or vasculitis are at increased risk of COVID-19 [11].…”